Biotech News

Artelo Biosciences Regains Compliance with Nasdaq Listing Requirements

Artelo Biosciences (ARTL)Artelo Biosciences2026-06-25 13:46 ESTCompany update

ARTL (ARTL) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is artl.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

ARTLArtelo Biosciences2026-06-25 13:46 EST

Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success

ARTLArtelo Biosciences2026-06-25 13:46 EST

Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results

ARTLArtelo Biosciences2026-06-25 13:46 EST

Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate

ARTLArtelo Biosciences2026-06-25 13:46 EST

Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results

ARTLArtelo Biosciences2026-06-25 13:46 EST

Artelo Biosciences Announces Reverse Stock Split

ARTLArtelo Biosciences2026-06-25 13:46 EST

Artelo Announces Third-Party Fully Funded Clinical Study Agreement to Evaluate ART27.13 in Glaucoma Patients

ARTLArtelo Biosciences2026-06-25 13:46 EST

Artelo Biosciences Expands ART27.13 Development as a Potential Companion Therapy to GLP-1 Treatments

ARTLArtelo Biosciences2026-06-25 13:46 EST

Artelo Biosciences Announces $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

ARTLArtelo Biosciences2026-06-25 13:46 EST

Artelo Biosciences Announces Closing of $11.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

ARTLArtelo Biosciences2026-06-25 13:46 EST

Artelo Biosciences Announces Strategic Collaboration with Artificial Intelligence (AI) Leader ScienceMachine Highlighting New Expansion Opportunities and Insights for FABP5 Inhibitor Development

View all latest news

Artelo Biosciences

Artelo Biosciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ARTLArtelo Biosciences2026-06-26 07:10 EST

Artelo Biosciences Presents ART26.12 Human Metabolite Data Demonstrating Favorable Drug Metabolism Characteristics Associated with Clinical Development Success

ARTLArtelo Biosciences2026-06-26 07:10 EST

Artelo Biosciences Provides Business Update Outlining Upcoming Milestones and Reports 2026 First Quarter Financial Results

ARTLArtelo Biosciences2026-06-26 07:10 EST

Artelo Bioscience Commends Presidential Executive Order Expanding CBD Research and Access; Highlights ART12.11 as a Leading Pharmaceutical-Grade Cannabidiol Candidate

ARTLArtelo Biosciences2026-06-26 07:10 EST

Artelo Biosciences Provides Business Update Highlighting Clinical Progress and Reports Fiscal 2025 Year-End Financial Results

ARTLArtelo Biosciences2026-06-26 07:10 EST

Artelo Biosciences Announces Reverse Stock Split

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States